The Efficacy of High Density Formula 1.5 kcal/ml or 1 kcal/ml On Catch Up Growth In Growth Faltering Children
Launched by UNIVERSITAS AIRLANGGA · Nov 29, 2023
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
This research is a retrospective observational study using medical record data from the EMR Husada Utama Hospital. Based on the EMR, data will be taken on patients who are able to consume 300-400 kcal of solid food, given 400 cc ONS 1.5 kkal/ml (Nutrini drink) equivalent to 600 kcal as group 1. Patients who are able to consume 500-600 kcal solid food are given 1 kkal/ml 400 cc ONS (SGM optigrow) equivalent 400 kcal as group 2. The rate of increase body weight and body height will be measured at day 0, 30 , 60 and 90 after consumed high dense formula, then it will be plotted in WHO Growth Ch...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children aged 1 years - 5 years, are diagnosed tuberculosis (TB) and urinary tract infection (UTI)
- • Children who have feeding difficulties
- • Children who malnourished or have undergoing weight malnutrition
- Exclusion Criteria:
- • Children with fluid retention
- • Children with organomegaly
- • Children with tumor masses.
- • Children with congenital abnormalities
- • Children wither cerebral palsy, hormonal disorders, and syndromes.
About Universitas Airlangga
Universitas Airlangga, a prestigious institution located in Surabaya, Indonesia, is dedicated to advancing medical research and education. As a clinical trial sponsor, the university leverages its strong academic foundation and commitment to innovation to conduct rigorous and ethical clinical studies. With a focus on improving healthcare outcomes, Universitas Airlangga collaborates with various stakeholders, including healthcare professionals and industry partners, to explore new therapies and enhance patient care. Their research initiatives are aligned with global standards, ensuring the integrity and reliability of their findings in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Surabaya, East Java, Indonesia
Patients applied
Trial Officials
Nur Aisiyah Widjaja, Ph.D
Principal Investigator
Child Health Department, Faculty of Medicine, Universitas Airlangga
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported